Mass drug administration with dihydroartemisininpiperaquine and malaria transmission dynamics in the gambia: A prospective cohort study

Clinical Infectious Diseases

Volumn 69, Issue 2, 2019, Pages 278-286

  Mwesigwa, Julia ^a,b   Achan, Jane ^a   Affara, Muna ^a   Wathuo, Miriam ^a   Worwui, Archibald ^a   Mohammed, Nuredin Ibrahim ^a   Kanuteh, Fatoumatta ^a   Prom, Aurelia ^a   Dierickx, Susan ^c   Di Tanna, Gian Luca ^d   Nwakanma, Davis ^a   Bousema, Teun ^e   Drakeley, Chris ^a   Van Geertruyden, Jean Pierre ^b   D'Alessandro, Umberto ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d UNIVERSITY OF BARCELONA   (Spain)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical malaria; Dihydroartemisinin piperaquine; Gametocytes; Malaria infection; Mass drug administration

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; HEMOGLOBIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; BLOOD SAMPLING; BLOOD SMEAR; BODY WEIGHT; CHILD; CHILL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DRIED BLOOD SPOT TESTING; FEMALE; FEVER; GAMBIA; GAMETOCYTE; HEADACHE; HEALTH CARE FACILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALAISE; MALARIA; MALE; MASS DRUG ADMINISTRATION; MEDICATION COMPLIANCE; NESTED POLYMERASE CHAIN REACTION; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REINFECTION; REVIEW; RISK FACTOR; VOMITING; ADULT; AGED; DISEASE TRANSMISSION; HEALTH SERVICES RESEARCH; INFANT; MIDDLE AGED; PRESCHOOL CHILD; RISK ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; GAMBIA; HEALTH SERVICES RESEARCH; HUMANS; INCIDENCE; INFANT; MALARIA; MALE; MASS DRUG ADMINISTRATION; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; QUINOLINES; RISK ASSESSMENT; YOUNG ADULT;

EID: 85069267982     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy870     Document Type: Review

References (42)

1. World Health Organization. World malaria report 2017. Geneva, Switzerland: World Health Organization, 2017.
2. Daniels R F, Deme AB, Gomis J F, et al. Evidence of non-Plasmodium falciparum malaria infection in Kédougou, Sénégal. Malar J 2017; 16:9.
3. Williams J, Njie F, Cairns M, et al. Non-falciparum malaria infections in pregnant women in West Africa. Malar J 2016; 15:53.
4. Ceesay SJ, Casals-Pascual C, Nwakanma DC, et al. Continued decline of malaria in The Gambia with implications for elimination. PLoS One 2010; 5:e12242.
5. Mwesigwa J, Okebe J, Affara M, et al. On-going malaria transmission in The Gambia despite high coverage of control interventions: a nationwide cross-sectional survey. Malar J 2015; 14:314.
6. Satoguina J, Walther B, Drakeley C, et al. Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J 2009; 8:274.
7. Okebe J, Affara M, Correa S, et al. School-based countrywide seroprevalence survey reveals spatial heterogeneity in malaria transmission in the Gambia. PLoS One 2014; 9:e110926.
8. Mwesigwa J, Achan J, Di Tanna GL, et al. Residual malaria transmission dynamics varies across The Gambia despite high coverage of control interventions. PLoS One 2017; 12:e0187059.
9. World Health Organization and Global Malaria Programme. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria, 2015. Geneva, Switzerland: World Health Organization, 2015.
10. Poirot E1, Skarbinski J, Sinclair D, Kachur S P, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev 2013; 9:1-160.
11. World Health Organization. Mass drug administration for malaria: a practical field manual. Geneva, Switzerland: World Health Organization, 2017.
12. Gerardin J, Eckhoff P, Wenger EA. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination. BMC Infect Dis 2015; 15:144.
13. Hung T Y, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57:253-62.
14. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014: 1-160.
15. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after arte-mether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013; 207:1637-45.
16. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and arte-mether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009; 4:e7871.
17. Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17:184-93.
18. Theander TG. Unstable malaria in Sudan: the influence of the dry season. Malaria in areas of unstable and seasonal transmission. Lessons from Daraweesh. Trans R Soc Trop Med Hyg 1998; 92:589-92.
19. Snounou G. Genotyping of Plasmodium spp. Nested PCR. Methods Mol Med 2002; 72:103-16.
20. Rabinovich RN, Drakeley C, Djimde AA, et al. malERA: An updated research agenda for malaria elimination and eradication. PLoS Med 2017; 14:e1002456.
21. Stata Technical Support. Stata Statistical Software: Release 13, StataCorp, Editor 2013. College Station, TX: StataCorp L P, 2013.
22. Caputo B, Nwakanma D, Jawara M, et al. Anopheles gambiae complex along The Gambia river, with particular reference to the molecular forms of An. gambiae s.s. Malar J 2008; 7:182.
23. Brady OJ, Slater HC, Pemberton-Ross P, et al. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health 2017; 5:e680-7.
24. Smit MR, Ochomo EO, Aljayyoussi G, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-pipera-quine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2018; 18:615-26.
25. Pindolia DK, Garcia AJ, Wesolowski A, et al. Human movement data for malaria control and elimination strategic planning. Malar J 2012; 11:205.
26. Martens P, Hall L. Malaria on the move: human population movement and malaria transmission. Emerg Infect Dis 2000; 6:103-9.
27. Peeters Grietens K, Gryseels C, Dierickx S, et al. Characterizing types of human mobility to inform differential and targeted malaria elimination strategies in Northeast Cambodia. Sci Rep 2015; 5:16837.
28. von Seidlein L, Walraven G, Milligan PJ, et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg 2003; 97:217-25.
29. Shekalaghe SA, Drakeley C, van den Bosch S, et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J 2011; 10:247.
30. Eisele T P, Bennett A, Silumbe K, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on Malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis 2016; 214:1831-9.
31. Landier J, Kajeechiwa L, Thwin MM, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar. Wellcome Open Res 2017; 2:81.
32. Dierickx S, Gryseels C, Mwesigwa J, et al. Factors associated with non-participation and non-adherence in directly observed mass drug administration for Malaria in The Gambia. PLoS One 2016; 11:e0148627. doi:10.1371/journal. pone.0148627
33. Dial NJ, Ceesay SJ, Gosling RD, D'Alessandro U, Baltzell KA. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J 2014; 13:47. doi:10.1186/1475-2875-13-47
34. Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg 2015; 93:125-34.
35. The WorldWide Antimalarial Resistance Network DP Study Group. Correction: the effect of dosing regimens on the antimalarial efficacy of dihydroartemisi-nin-piperaquine: a pooled analysis of individual patient data. PLoS Med 2013; 10:137.
36. Beshir KB, Sutherland CJ, Sawa P, et al. Residual Plasmodium falciparum parasit-emia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 2013; 208:2017-24.
37. Chang HH, Meibalan E, Zelin J, et al. Persistence of Plasmodium falciparum par-asitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Sci Rep 2016; 6:26330.
38. Wanzirah H, Tusting LS, Arinaitwe E, et al. Mind the gap: house structure and the risk of malaria in Uganda. PLoS One 2015; 10:e0117396.
39. Staedke SG, Nottingham E W, Cox J, Kamya MR, Rosenthal PJ, Dorsey G. Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg 2003; 69:244-6.
40. Littrell M, Sow GD, Ngom A, et al. Case investigation and reactive case detection for malaria elimination in northern Senegal. Malar J 2013; 12:331.
41. Stresman GH, Baidjoe AY, Stevenson J, et al. Focal Screening to Identify the Subpatent Parasite Reservoir in an Area of Low and Heterogeneous Transmission in the Kenya Highlands. J Infect Dis 2015; 212:1768-77.
42. World Health Organization, Malaria Rapid Diagnostic Test Performance, Results of WHO product testing of malaria RDTs: round 6 (2014-2015), 1-154. Geneva: World Health Organization; 2015.